APA (7th ed.) Citation

Davies, M. A., Saiag, P., Robert, C., Grob, J., Flaherty, K. T., Arance, A., . . . Long, G. V. (2017). Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. The lancet oncology, 18(7), 863-873. https://doi.org/10.1016/S1470-2045(17)30429-1

Chicago Style (17th ed.) Citation

Davies, Michael A., et al. "Dabrafenib Plus Trametinib in Patients with BRAFV600-mutant Melanoma Brain Metastases (COMBI-MB): A Multicentre, Multicohort, Open-label, Phase 2 Trial." The Lancet Oncology 18, no. 7 (2017): 863-873. https://doi.org/10.1016/S1470-2045(17)30429-1.

MLA (9th ed.) Citation

Davies, Michael A., et al. "Dabrafenib Plus Trametinib in Patients with BRAFV600-mutant Melanoma Brain Metastases (COMBI-MB): A Multicentre, Multicohort, Open-label, Phase 2 Trial." The Lancet Oncology, vol. 18, no. 7, 2017, pp. 863-873, https://doi.org/10.1016/S1470-2045(17)30429-1.